Sarcopenia Identified According to the EWGSOP2 Definition in Community-Living People: Prevalence and Clinical Features.


Journal

Journal of the American Medical Directors Association
ISSN: 1538-9375
Titre abrégé: J Am Med Dir Assoc
Pays: United States
ID NLM: 100893243

Informations de publication

Date de publication:
10 2020
Historique:
received: 17 09 2019
revised: 09 03 2020
accepted: 09 03 2020
pubmed: 4 5 2020
medline: 24 6 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

The European Working Group on Sarcopenia in Older People (EWGSOP2) recently updated the definition of sarcopenia in order to reflect scientific and clinical evidences. The aim is to explore the prevalence of sarcopenia (according to the new EWGSOP2 definition) and related risk factors among an unselected sample of subjects living in community. The Longevity Check-up 7+ project is an ongoing cross-sectional study started in June 2015 and conducted in unconventional settings (ie, exhibitions, malls, and health promotion campaigns). Candidate participants are eligible for enrollment if they are at least 18 years of age. Muscle strength was assessed by handgrip strength and physical performance was evaluated by chair stand test. The mean age of 11,253 subjects was 55.6 (standard deviation 11.5, from 18 to 98 years) years, and 6356 (56%) were women. Using the EWGSOP2 algorithm, 973 participants (8.6%) were identified as affected by sarcopenia, and the prevalence of sarcopenia significantly increased with age. Sarcopenia was associated with diabetes prevalence ratio (PR) 1.42, 95% confidence interval (CI) 1.06-1.89, impairment in 400-m walking performance (PR 2.16, 95% CI 1.74-2.17), and self-reported unhealthy status (PR 1.77, 95% CI 1.45-2.17). Conversely, a decreased probability of being sarcopenic was detected among subjects following a healthy diet (PR 0.79, 95% CI 0.63-0.98) and involved in regular physical activity (PR 0.79, 95% CI 0.64-0.99). Muscle strength and physical performance assessment should be considered as the recommended methods for the early detection of individuals at risk of probable sarcopenia.

Sections du résumé

BACKGROUND
The European Working Group on Sarcopenia in Older People (EWGSOP2) recently updated the definition of sarcopenia in order to reflect scientific and clinical evidences.
OBJECTIVE
The aim is to explore the prevalence of sarcopenia (according to the new EWGSOP2 definition) and related risk factors among an unselected sample of subjects living in community.
SETTING AND PARTICIPANTS
The Longevity Check-up 7+ project is an ongoing cross-sectional study started in June 2015 and conducted in unconventional settings (ie, exhibitions, malls, and health promotion campaigns). Candidate participants are eligible for enrollment if they are at least 18 years of age.
METHODS
Muscle strength was assessed by handgrip strength and physical performance was evaluated by chair stand test.
RESULTS
The mean age of 11,253 subjects was 55.6 (standard deviation 11.5, from 18 to 98 years) years, and 6356 (56%) were women. Using the EWGSOP2 algorithm, 973 participants (8.6%) were identified as affected by sarcopenia, and the prevalence of sarcopenia significantly increased with age. Sarcopenia was associated with diabetes prevalence ratio (PR) 1.42, 95% confidence interval (CI) 1.06-1.89, impairment in 400-m walking performance (PR 2.16, 95% CI 1.74-2.17), and self-reported unhealthy status (PR 1.77, 95% CI 1.45-2.17). Conversely, a decreased probability of being sarcopenic was detected among subjects following a healthy diet (PR 0.79, 95% CI 0.63-0.98) and involved in regular physical activity (PR 0.79, 95% CI 0.64-0.99).
CONCLUSIONS AND IMPLICATIONS
Muscle strength and physical performance assessment should be considered as the recommended methods for the early detection of individuals at risk of probable sarcopenia.

Identifiants

pubmed: 32359893
pii: S1525-8610(20)30252-8
doi: 10.1016/j.jamda.2020.03.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1470-1474

Informations de copyright

Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Anna Maria Martone (AM)

Università Cattolica del Sacro Cuore, Institute of Internal Medicine and Geriatrics, Rome, Italy, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.

Emanuele Marzetti (E)

Università Cattolica del Sacro Cuore, Institute of Internal Medicine and Geriatrics, Rome, Italy, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.

Sara Salini (S)

Università Cattolica del Sacro Cuore, Institute of Internal Medicine and Geriatrics, Rome, Italy, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.

Maria Beatrice Zazzara (MB)

Università Cattolica del Sacro Cuore, Institute of Internal Medicine and Geriatrics, Rome, Italy, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.

Luca Santoro (L)

Università Cattolica del Sacro Cuore, Institute of Internal Medicine and Geriatrics, Rome, Italy, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.

Matteo Tosato (M)

Università Cattolica del Sacro Cuore, Institute of Internal Medicine and Geriatrics, Rome, Italy, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.

Anna Picca (A)

Università Cattolica del Sacro Cuore, Institute of Internal Medicine and Geriatrics, Rome, Italy, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.

Riccardo Calvani (R)

Università Cattolica del Sacro Cuore, Institute of Internal Medicine and Geriatrics, Rome, Italy, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.

Francesco Landi (F)

Università Cattolica del Sacro Cuore, Institute of Internal Medicine and Geriatrics, Rome, Italy, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy. Electronic address: francesco.landi@unicatt.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH